China Oncology ›› 2024, Vol. 34 ›› Issue (2): 191-200.doi: 10.19401/j.cnki.1007-3639.2024.02.007
• Article • Previous Articles Next Articles
LIU Zhiyu1,2(), XU Dong1,2, CHEN Xihao1,2, LI Jipeng2()
Received:
2023-03-15
Revised:
2023-12-15
Online:
2024-02-29
Published:
2024-03-14
Contact:
LI Jipeng
CLC Number:
LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng. Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. China Oncology, 2024, 34(2): 191-200.
Tab. 1
Clinical baseline characteristics of patients with LARC [n (%)]"
Characteristic | Good tumor regression (n=98) | Bad tumor regression (n=60) | P value |
---|---|---|---|
Gender | 0.183 9 | ||
Female | 34 (34.69) | 14 (23.33) | |
Male | 64 (65.31) | 46 (76.67) | |
Age/year | 0.066 3 | ||
<71.5 | 93 (94.90) | 51 (85.00) | |
≥71.5 | 5 (5.10) | 9 (15.00) | |
Albumin/(g·L-1) | 0.065 7 | ||
<38.1 | 2 (2.04) | 6 (10.00) | |
≥38.1 | 96 (97.96) | 54 (90.00) | |
PNI | 0.032 4 | ||
<46.175 | 6 (6.12) | 11 (18.33) | |
≥46.175 | 92 (93.88) | 49 (81.67) | |
Fibrinogen/(g·L-1) | 0.003 0 | ||
<4.13 | 81 (82.65) | 36 (60.00) | |
≥4.13 | 17 (17.35) | 24 (40.00) | |
D-dimer/(ng·mL-1) | 0.044 7 | ||
<275 | 50 (51.02) | 20 (33.33) | |
≥275 | 48 (48.98) | 40 (66.67) | |
FAR | 0.023 0 | ||
<0.095 | 78 (79.59) | 37 (61.67) | |
≥0.095 | 20 (20.41) | 23 (38.33) | |
CEA/(ng·mL-1) | 0.004 8 | ||
<2.11 | 23 (23.47) | 3 (5.00) | |
≥2.11 | 75 (76.53) | 57 (95.00) | |
CA19-9/(U·mL-1) | 0.145 5 | ||
<8.365 | 35 (35.71) | 14 (23.33) | |
≥8.365 | 63 (64.29) | 46 (76.67) | |
CA12-5/(U·mL-1) | 0.429 0 | ||
<14.765 | 77 (78.57) | 51 (85.00) | |
≥14.765 | 21 (21.43) | 9 (15.00) | |
FOBT | 0.268 9 | ||
Negative | 19 (19.39) | 17 (28.33) | |
Positive | 79 (80.61) | 43 (71.67) | |
MRF | 0.633 5 | ||
Negative | 41 (41.84) | 22 (36.67) | |
Positive | 57 (58.16) | 38 (63.33) | |
EMVI | 0.006 2 | ||
Negative | 67 (68.37) | 27 (45.00) | |
Positive | 31 (31.63) | 33 (55.00) | |
Time to surgery after nCRT/week M (P25, P75) | 8.000 (6.000, 8.000) | 6.500 (6.000, 8.000) | 0.016 4 |
Tumor diameter/cm | <0.000 1 | ||
<4.7 | 55 (56.12) | 12 (20.00) | |
≥4.7 | 43 (43.88) | 48 (80.00) | |
Distance from anal verge/cm | 0.821 9 | ||
>10 | 11 (11.22) | 5 (8.33) | |
5-10 | 47 (47.96) | 29 (48.33) | |
<5 | 40 (40.82) | 26 (43.33) | |
Tumor type | 0.261 5 | ||
Adenocarcinoma | 95 (96.94) | 55 (91.67) | |
Adenosine squamous carcinoma | 2 (2.04) | 2 (3.33) | |
Mucous membrane cancer | 1 (1.02) | 3 (5.00) | |
Degree of differentiation | 0.255 3 | ||
Well differentiated | 16 (16.33) | 7 (11.67) | |
Moderately differentiated | 63 (64.29) | 46 (76.67) | |
Poorly differentiated | 19 (19.39) | 7 (11.67) | |
T stage | 0.098 8 | ||
T2 | 11 (11.22) | 8 (13.33) | |
T3 | 76 (77.55) | 38 (63.33) | |
T4 | 11 (11.22) | 14 (23.33) | |
N stage | 0.778 2 | ||
N0 | 7 (7.14) | 6 (10.00) | |
N1 | 53 (54.08) | 30 (50.00) | |
N2 | 38 (38.78) | 24 (40.00) |
Tab. 2
nCRT and surgery in patients with LARC"
Therapeutic effect | pCR | Stage Ⅰ | Stage Ⅱ | Stage Ⅲ | Stage Ⅳ | Down stage rate/% | pCR rate/% | R0 resection rate/% |
---|---|---|---|---|---|---|---|---|
Good tumor regression (n = 98) | 62.2 | 15.3 | 99.0 | |||||
Pre-nCRT | 9 | 89 | ||||||
After-nCRT | 15 | 26 | 25 | 32 | ||||
Bad tumor regression (n = 60) | 48.3 | 1.6 | 96.7 | |||||
Pre-nCRT | 7 | 53 | ||||||
After-nCRT | 1 | 13 | 16 | 27 | 3 |
Tab. 3
Multivariable logistic analysis of tumor regression after nCRT in patients with LARC"
Characteristic | Estimate | SE | OR | 95% CI | P value |
---|---|---|---|---|---|
Fibrinogen≥4.13 g/L | 2.695 | 1.787 | 14.700 | 0.825-901.624 | 0.128 |
Time to surgery after nCRT/week | -0.297 | 0.108 | 0.743 | 0.590-0.908 | 0.006 |
CEA≥2.11 ng/mL | 2.281 | 0.792 | 9.873 | 2.400-57.230 | 0.004 |
Albumin<38.1 g/L | -0.415 | 1.394 | 0.657 | 0.044-11.745 | 0.766 |
PNI<46.175 | -1.942 | 0.925 | 6.996 | 1.152-47.615 | 0.035 |
D-dimer≥275 ng/mL | 1.241 | 0.496 | 3.487 | 1.352-9.583 | 0.010 |
EMVI positive | 0.990 | 0.446 | 2.683 | 1.137-6.615 | 0.026 |
Tumor diameter<4.7 cm | -3.022 | 0.696 | 0.048 | 0.011-0.166 | <0.001 |
FAR≥0.095 | -0.732 | 1.810 | 0.488 | 0.009-11.359 | 0.686 |
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3 |
[2] | National Health Commission of the People’s Republic of China, Chinese Society of Oncology. Chinese protocol of diagnosis and treatment of colorectal cancer (2023 edition)[J]. Chin J Surg, 2023, 61(8): 617-644. |
[3] |
KENNEDY A, COHN M, COLDWELL D M, et al. Erratum to updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases[J]. J Gastrointest Oncol, 2018, 9(2): E13-E14.
doi: 10.21037/jgo |
[4] |
BENSON A B, VENOOK A P, AL-HAWARY M M, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(10): 1139-1167.
doi: 10.6004/jnccn.2022.0051 |
[5] |
GÉRARD J P, CONROY T, BONNETAIN F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203[J]. J Clin Oncol, 2006, 24(28): 4620-4625.
doi: 10.1200/JCO.2006.06.7629 |
[6] |
BOSSET J F, COLLETTE L, CALAIS G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer[J]. N Engl J Med, 2006, 355(11): 1114-1123.
doi: 10.1056/NEJMoa060829 |
[7] |
MAAS M, NELEMANS P J, VALENTINI V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data[J]. Lancet Oncol, 2010, 11(9): 835-844.
doi: 10.1016/S1470-2045(10)70172-8 pmid: 20692872 |
[8] |
AGARWAL A, CHANG G J, HU C Y, et al. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy[J]. Cancer, 2013, 119(24): 4231-4241.
doi: 10.1002/cncr.28331 pmid: 24089344 |
[9] |
MCCOY M J, HEMMINGS C, ANYAEGBU C C, et al. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response[J]. Oncotarget, 2017, 8(12): 19803-19813.
doi: 10.18632/oncotarget.15048 pmid: 28177891 |
[10] |
YI Y X, SHEN L J, SHI W, et al. Gut microbiome components predict response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a prospective, longitudinal study[J]. Clin Cancer Res, 2021, 27(5): 1329-1340.
doi: 10.1158/1078-0432.CCR-20-3445 pmid: 33298472 |
[11] |
EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
doi: 10.1016/j.ejca.2008.10.026 pmid: 19097774 |
[12] |
PARK I J, YOU Y N, AGARWAL A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer[J]. J Clin Oncol, 2012, 30(15): 1770-1776.
doi: 10.1200/JCO.2011.39.7901 pmid: 22493423 |
[13] | ZENG W G, LIANG J W, WANG Z, et al. Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer[J]. Chin J Cancer, 2015, 34(10): 468-474. |
[14] |
BUGG W G, ANDREOU A K, BISWAS D, et al. The prognostic significance of MRI-detected extramural venous invasion in rectal carcinoma[J]. Clin Radiol, 2014, 69(6): 619-623.
doi: 10.1016/j.crad.2014.01.010 pmid: 24581964 |
[15] |
MCCAWLEY N, CLANCY C, O’NEILL B D, et al. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: a systematic review and meta-analysis[J]. Dis Colon Rectum, 2016, 59(12): 1200-1208.
pmid: 27824706 |
[16] |
SONG M, LI S, WANG H Z, et al. MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer[J]. Br J Cancer, 2022, 127(2): 249-257.
doi: 10.1038/s41416-022-01786-7 |
[17] | FENG L L, LIU Z Y, LI C F, et al. Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study[J]. Lancet Digit Health, 2022, 4(1): e8-e17. |
[18] |
BEDRIKOVETSKI S, TRAEGER L, VATHER R, et al. Clinical and biochemical predictors of tumor response after neoadjuvant therapy in rectal cancer[J]. Asia Pac J Clin Oncol, 2023, 19(3): 365-373.
doi: 10.1111/ajco.v19.3 |
[19] |
GAMBACORTA M A, MASCIOCCHI C, CHILOIRO G, et al. Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials[J]. Radiother Oncol, 2021, 154: 154-160.
doi: 10.1016/j.radonc.2020.09.026 pmid: 32966845 |
[20] |
HUANG W H, WANG S G, ZHANG H, et al. Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer[J]. Cancer Biol Med, 2018, 15(1): 88-96.
doi: 10.20892/j.issn.2095-3941.2017.0124 pmid: 29545972 |
[21] |
BEER J H, HAEBERLI A, VOGT A, et al. Coagulation markers predict survival in cancer patients[J]. Thromb Haemost, 2002, 88(5): 745-749.
doi: 10.1055/s-0037-1613296 |
[22] |
SHIBUTANI M, KASHIWAGI S, FUKUOKA T, et al. The significance of the D-dimer level as a prognostic marker for survival and treatment outcomes in patients with stage Ⅳ colorectal cancer[J]. In Vivo, 2023, 37(1): 440-444.
doi: 10.21873/invivo.13097 |
[23] |
MUSCARITOLI M, ARENDS J, BACHMANN P, et al. ESPEN practical guideline: clinical nutrition in cancer[J]. Clin Nutr, 2021, 40(5): 2898-2913.
doi: 10.1016/j.clnu.2021.02.005 pmid: 33946039 |
[24] |
XIE H L, WEI L S, YUAN G H, et al. Prognostic value of prognostic nutritional index in patients with colorectal cancer undergoing surgical treatment[J]. Front Nutr, 2022, 9: 794489.
doi: 10.3389/fnut.2022.794489 |
[25] | HU H B, KANG L, ZHANG J W, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(1): 38-48. |
[26] |
SAUER R, BECKER H, HOHENBERGER W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. N Engl J Med, 2004, 351(17): 1731-1740.
doi: 10.1056/NEJMoa040694 |
[27] |
MOMMA T, OKAYAMA H, KANKE Y, et al. Validation of gene expression-based predictive biomarkers for response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Cancers (Basel), 2021, 13(18): 4642.
doi: 10.3390/cancers13184642 |
[28] |
GARCIA-AGUILAR J, CHOW O S, SMITH D D, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial[J]. Lancet Oncol, 2015, 16(8): 957-966.
doi: 10.1016/S1470-2045(15)00004-2 |
[29] |
CERCEK A, ROXBURGH C S D, STROMBOM P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer[J]. JAMA Oncol, 2018, 4(6): e180071.
doi: 10.1001/jamaoncol.2018.0071 |
[1] | Colorectal Cancer Special Committee of Shanghai Anti-Cancer Association . Shanghai plan for early screening, diagnosis and treatment of colorectal cancer (2023 edition) [J]. China Oncology, 2024, 34(1): 13-66. |
[2] | WU Han, XU Lei, WANG Miaomiao, ZHANG Ruizhe, XU Xiaoyang, GUO Ningjie, WU Shuhua. Correlation of LC3 and the recruitment of dendritic cell and the formation of TLS in colorectal cancer and its clinical significance [J]. China Oncology, 2023, 33(9): 818-828. |
[3] | ZHOU Cong, HE Lina, CHENG Xiaojiao, HUANG Tinglei, TU Shuiping. Effect of RSPO3 on inhibiting the growth of colorectal cancer transplanted tumors and increasing NK cell infiltration in vivo [J]. China Oncology, 2023, 33(7): 664-672. |
[4] | YE Junling, ZHENG Xiaoying, GUO Xinjian, CHEN Ruihui, YANG Liu, GOU Xiaodan, JIANG Hanmei. A study on mechanism of lncRNA-mediated SNHG5/miR-26a-5p/MTDH signal axis promoting metastasis of colorectal cancer [J]. China Oncology, 2023, 33(7): 673-685. |
[5] | DONG Xiaohuan, LIU Jun, LI Hongxuan, CHENG Yan, LI Yue, YU Wen, CAI Xuwei, FU Xiaolong. Preliminary study on involving field irradiation radiotherapy in neoadjuvant chemoradiotherapy for esophageal cancer [J]. China Oncology, 2023, 33(3): 267-273. |
[6] | CAI Jialuo, ZHU Ruiqiu, LI Sen, CAO Yijun, HUANG Fang. Mechanism of inflammatory cancer-associated fibroblast-mediated drug resistance in colorectal cancer cells [J]. China Oncology, 2023, 33(12): 1065-1072. |
[7] | CHEN Xi, ZENG Xiaoying, CHEN Jiayan, LIU Fei, TANG Xi. The clinical value of mismatch repair protein combined with serum tumor markers and Ki-67 proliferation index in the prognostic evaluation of colorectal cancer [J]. China Oncology, 2022, 32(3): 243-250. |
[8] | CUI Zhongze, HE Shuang, WEN Feifei, LI Yangyang, XU Xiaoyang, LU Lizhen, WU Shuhua. Experimental study on influence of autophagy on DPD expression and its effect on chemotherapy with 5-FU in colorectal cancer [J]. China Oncology, 2022, 32(12): 1199-1209. |
[9] | WANG Jun, HE Ping. Prognostic value of perineural invasion in ypⅠ-Ⅱ rectal cancer patients who received neoadjuvant radiotherapy [J]. China Oncology, 2022, 32(12): 1229-1234. |
[10] | WANG Qian, ZHANG Jing, YU Chengli, BAO Longlong, CAI Xu, JIANG Wenhua, HUANG Dan, SHENG Weiqi, ZHU Xiaoli, ZHOU Xiaoyan, BAI Qianming. Validation of the fully automated IdyllaTM system for microsatellite instability detection in Chinese colorectal cancers [J]. China Oncology, 2022, 32(11): 1084-1090. |
[11] | JIA Zhenzhen, HE Shuang, LI Yangyang, WEN Feifei, XU Xiaoyang, GUO Ningjie, WU Shuhua. Correlations between expressions of DPD, LC3 and P62 in colorectal cancer and their clinical significance [J]. China Oncology, 2022, 32(1): 24-33. |
[12] | MA Yifei , LIANG Xinjun , WEI Shaozhong . Prognostic value of inflammatory and immune markers in resectable colorectal cancer [J]. China Oncology, 2021, 31(9): 845-851. |
[13] | ZHU Yihui, LI Ting, HU Xichun. Clinical research progress and prospect of trastuzumab deruxtecan [J]. China Oncology, 2021, 31(8): 754-761. |
[14] | ZHANG Yingqiang , LIN Yansong . Application and research progress of 90 Y microspheres internal radiation therapy in colorectal cancer with liver metastasis [J]. China Oncology, 2021, 31(8): 762-768. |
[15] | HUA Qing, SHEN Xuefang, XU Pingbo . Effect of KLK8 on apoptosis of colorectal cancer cells by regulating EGF and its mechanism [J]. China Oncology, 2021, 31(5): 383-389. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd